Saturday 7 November 2026 Export XFOR’s income statement to Excel — free account

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.1 million, up 1,273.2% from fiscal 2024.

Revenue: +63.1%
EPS: +76.9%
Free cash flow: +27.5%
Total debt: +1.24%

Quarter to September 2026, against a year earlier

Insider buying

3.15 0.08 +2.61%

Follow XFOR

Alert me

Market cap: $304.4M
P/E: 0.0×
Fwd P/E: −5.0×
Dividend yield: —
F-score: n/a
Altman Z: −1.78
Beneish M: 8.05
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.01

Sold, $m 0.46

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	1	—
Sell	—	—	—	—	—	1	1	—	2	—	1	—

Insider Ownership 40.68%

Capital & Financial Ratios $m

Size

Market Cap 304.38

Revenue ttm 16.96

Net income ttm (80.52)

Free cash flow ttm (81.10)

Net debt Q (110.69)

Valuation

P/E 0.00

Forward P/E (5.01)

Price / sales 23.50

Forward P/S Powerpack

Price / FCF 16.91

Price / book 2.87

Financial health

Current ratio Q 13.22

Debt / equity Q 0.55

Interest coverage Q (9.11)

Growth

Revenue growth Q +63.12%

Operating income growth Q +27.33%

EPS, this year +65.56%

EPS, next year A −18.01%

Revenue, next year A −54.49%

EPS, past 5 yrs —

EPS, next 5 yrs A +23.26%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 79.24%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	114	102	253	188
Receivables	1	2	1	1
Inventory	—	3	4	6
Other	—	—	—	—
	122	112	262	198

	2023	2024	2025	Q'26
Payables	9	9	6	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	23	33	26	15

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	115.68%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	20.67%	36.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.19 Actual −0.16

−0.39 −0.32 −0.24 −0.17 −0.10

Q4 FY25 Beat +0.14

Q1 FY26 Beat +0.04

Q2 FY26 Beat +0.06

Q3 FY26 Beat +0.03

Q4 FY26 — Mar 16

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−0.36	−0.22	Beat by 0.14
Q1 FY26	−0.20	−0.16	Beat by 0.04
Q2 FY26	−0.19	−0.13	Beat by 0.06
Q3 FY26	−0.19	−0.16	Beat by 0.03
Q4 FY26	−0.22	—	Reports 16 March 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.16)	(0.13)	(0.16)	—	—
’25	0.04	(3.47)	(0.69)	(0.22)	(1.87)
’24	(7.81)	13.51	(5.41)	(6.01)	(5.71)
’23	(4.80)	(9.91)	(0.35)	(3.00)	(17.12)
’22	(21.62)	(18.02)	(7.81)	(8.71)	(45.65)
’21	(39.04)	(22.22)	(22.82)	(37.24)	(119.82)
’20	(16.82)	(22.82)	(26.13)	(27.33)	(92.79)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	9	3	—	—
’25	29	2	2	3	35
’24	—	1	1	1	3
’20	3	—	—	—	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(20)	(21)	(20)	—	—
’25	(12)	(30)	(28)	(16)	(86)
’24	(34)	(30)	(34)	(33)	(131)
’23	(27)	(21)	(21)	(28)	(97)
’22	(20)	(18)	(19)	(19)	(77)
’21	(18)	(19)	(14)	(19)	(71)
’20	(16)	(11)	(14)	(18)	(59)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(20)	(26)	(20)	—	—
’25	(15)	(30)	(28)	(16)	(89)
’24	(34)	68	(34)	(33)	(33)
’23	(27)	(21)	(21)	(28)	(97)
’22	(20)	(19)	(19)	(19)	(77)
’21	(19)	(19)	(14)	(19)	(72)
’20	(16)	(11)	(15)	(18)	(60)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	4	—	3	—	—	—	3	35	17		+39.0%	16	12	36	+1.2%
	Gross margin, %	—	—	100.00	—	100.00	—	—	—	68.83	83.60	81.77		(16.4) pt	Powerpack X4 Pharmaceuticals, Inc.’s next three years, line by line Analysts expect revenue to grow 1.2% a year to 2028 — slower than the 39.0% of the last 7 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(23)	(22)	(33)	(53)	(62)	(89)	(94)	(101)	(37)	(79)	(81)		+14.7%
	EBT margin, %	0.00	0.00	(951.00)	0.00	(2,066.10)	0.00	0.00	0.00	(1,452.48)	(225.44)	(474.71)		(225.4) pt
	Net income	(23)	(22)	(33)	(53)	(62)	(89)	(94)	(101)	(37)	(79)	(81)		+14.7%
Per share, $
Per share, $	Revenue	0.00	0.00	228.76	0.00	4.49	0.00	0.00	0.00	0.38	0.83	0.13		n/m
	Earnings	(8,059.58)	(1,637.16)	(2,177.67)	(139.04)	(92.79)	(119.82)	(45.65)	(17.12)	(5.71)	(1.87)	(0.67)		(60.5%)
	Cash flow	(7,461.72)	(1,392.88)	(1,661.44)	(125.18)	(87.97)	(82.70)	(36.45)	(16.28)	(19.53)	(2.02)	(0.60)		(59.8%)
	Capex	(25.17)	(24.71)	(2.22)	2.15	(2.04)	(0.72)	(0.05)	(0.01)	14.57	(0.07)	(0.04)		(47.9%)
	Free cash flow	(7,486.90)	(1,417.58)	(1,663.66)	(123.02)	(90.01)	(83.41)	(36.50)	(16.29)	(4.96)	(2.10)	(0.64)		(59.7%)
	Book value	(5,766.90)	3,837.06	(811.18)	336.60	108.88	75.12	35.01	8.62	3.30	4.40	1.10		n/m
	Shares, m	0	0	0	0	1	1	2	6	7	42	105		+190.2%
Valuation, ×
Valuation, ×	P/E	—	—	0.00	—	0.00	—	—	—	0.00	0.00	0.00		0.0
	P/S	—	—	0.00	—	0.00	—	—	—	26.55	4.82	23.50		7.8
	P/B	—	—	0.00	—	1.77	—	—	—	6.66	0.91	2.87		2.3
	EV/Sales	—	—	0.00	—	0.00	—	—	—	21.89	(0.19)	17.02		5.4
	EV/FCF	—	—	(0.32)	—	(1.40)	—	—	—	(4.64)	(0.42)	12.24		(1.7)
Cash, $m
Cash, $m	Operating cash flow	(22)	(21)	(25)	(48)	(59)	(71)	(77)	(97)	(131)	(86)	(76)		+16.5%
	Capex	0	0	0	1	(1)	(1)	0	0	98	(3)	(5)		+51.1%
	Free cash flow	(22)	(22)	(25)	(47)	(60)	(72)	(77)	(97)	(33)	(89)	(81)		+16.9%
Balance, $m
Balance, $m	Working capital	(6)	69	1	120	71	74	106	99	79	236	183		n/m
	Net debt	7	(67)	2	(105)	(46)	(48)	(88)	(60)	(27)	(177)	(111)		n/m
	Shareholders’ equity	(17)	59	(12)	129	73	64	74	51	22	186	139		n/m
Returns, %
Returns, %	ROA	(268.79)	(56.26)	(79.62)	(62.59)	(43.82)	(85.52)	(70.69)	(66.81)	(25.50)	(36.25)	(40.73)		+232.5 pt
	ROIC	0.00	0.00	0.00	(134.47)	(137.23)	(321.23)	0.00	0.00	0.00	(566.65)	(178.23)		(566.6) pt
	ROE	50.61	(2,330.44)	395.09	(204.85)	(61.51)	(149.61)	(139.26)	(161.67)	(102.26)	(75.99)	(80.32)		(126.6) pt
People
People	Employees	39	40	15	58	72	83	70	93	143	45	—		+1.6%
	Revenue/emp, $m	0.00	0.00	0.23	0.00	0.04	0.00	0.00	0.00	0.02	0.78	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PROK ProKidney Corp.	$322.0M	— (loss-making)	— (loss-making)	−32.13% (below 0%: shrinking)	n/m	−28.03% (below 0%: shrinking)	100.00%	(32,248.67%)	Compare
EIKN Eikon Therapeutics, Inc.	$316.3M	— (loss-making)	—	—	n/m	+15.18% (above 0%: growing)	—	0.00%	Compare
ALEC Alector, Inc.	$309.9M	6.6×	— (loss-making)	+4,895.89% (above 0%: growing)	n/m	+25.73% (above 0%: growing)	100.00%	76.04%	Compare
XFOR X4 Pharmaceuticals, Inc.	$304.4M	— (loss-making)	— (loss-making)	+63.12% (above 0%: growing)	n/m	+27.45% (above 0%: growing)	82.18%	(694.37%)
BNTC Benitec Biopharma Limited	$301.5M	— (loss-making)	— (loss-making)	−85.42% (below 0%: shrinking)	n/m	+38.90% (above 0%: growing)	0.00%	0.00%	Compare
GALT Galectin Therapeutics Inc.	$301.0M	— (loss-making)	—	—	n/m	+63.06% (above 0%: growing)	0.00%	0.00%	Compare
ENTA Enanta Pharmaceuticals, Inc.	$293.6M	— (loss-making)	— (loss-making)	−21.60% (below 0%: shrinking)	n/m	−157.51% (below 0%: shrinking)	100.00%	(120.04%)	Compare
SCTX Scribe Therapeutics Inc.	$293.1M	—	—	—	n/m	—	100.00%	(489.83%)	Compare
AGEN Agenus Inc.	$290.8M	10.7×	27.7×	+4.14% (above 0%: growing)	−99.00% (below 0%: shrinking)	−37.06% (below 0%: shrinking)	100.00%	36.23%	Compare
Median of peers	$301.2M	—	—	−21.60%	—	+15.18%	100.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 20 March 2026

Ownership

Directors and executive officers, together 1.13%

Funds managed by Empery Asset Management, LP 9.99%

FMR LLC 9.35%

Morgan Stanley 9.02%

Entities affiliated with Bain Capital Life Sciences Investors, LLC 8.08%

Coastland Capital Partners LP 7.27%

Saturn V Capital Management 7.08%

Entities affiliated with Perceptive Advisors LLC 6.52%

Entities affiliated with Growth Equity Opportunities 5.65%

Trails Edge Biotechnology Master Fund, LP 5.59%

Deep Track Biotechnology Master Fund, Ltd. 5.56%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

X4 Pharmaceuticals, Inc. (XFOR) Latest News

4 Nov

Impact 3 · 4:15 PM · GlobeNewswire

X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

29 Oct

Impact 4 · 4:30 PM · GlobeNewswire

X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day

Impact 4 · 4:14 PM · MarketBeat

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

9 Oct

Impact 3 · 7:00 AM · GlobeNewswire

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

8 Oct

Impact 4 · 8:30 AM · InvestorsHub

X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures

Impact 4 · 7:00 AM · GlobeNewswire

X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures

24 Sep

Impact 3 · 8:35 AM · Zacks

Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround

8 Sep

Impact 4 · 7:00 AM

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

6 Aug

Impact 3 · 7:10 PM

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

Impact 3 · 4:15 PM

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Impact 3 · 4:15 PM

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

21 May

Impact 4 · 12:33 AM · Simply Wall St.

How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

18 May

Impact 3 · 12:00 PM · Zacks

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

6 May

Impact 3 · 8:25 AM · Zacks

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

Impact 3 · 7:15 AM · GlobeNewswire

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

29 Apr

Impact 5 · 7:00 AM · GlobeNewswire

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

17 Mar

Impact 4 · 7:34 AM · Associated Press Finance

X4 Pharmaceuticals: Q4 Earnings Snapshot

Impact 4 · 7:15 AM · GlobeNewswire

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Impact 3 · 8:25 AM · Zacks

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

27 Feb

Impact 4 · 7:00 AM · GlobeNewswire

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

16 Feb

Impact 4 · 3:04 AM · MarketBeat

X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan

3 Feb

Impact 3 · 7:00 AM · GlobeNewswire

X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026

12 Jan

Impact 4 · 12:00 PM · Zacks

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy

24 Dec

Impact 3 · 9:55 AM · Zacks

Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?

8 Dec

Impact 4 · 6:04 AM

Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring Moves

24 Nov

Impact 4 · 3:07 AM · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing

18 Nov

Impact 4 · 10:39 AM · GlobeNewswirePharmaceutical TechnologyClinical Trials ArenaMedical Device NetworkZacks

WHIM Syndrome Research Analysis Report 2025-2035: Market Advances as X4 Pharmaceuticals Leads Innovation in CXCR4-Targeted Therapies

5 Nov

Impact 3 · 4:01 PM · GlobeNewswireAssociated Press FinanceZacksMT NewswiresZacksMT NewswiresInsider Monkey

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

Impact 3 · 8:15 AM · Zacks

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates

Impact 3 · 7:22 AM · Associated Press Finance

X4 Pharmaceuticals: Q3 Earnings Snapshot

X4 Pharmaceuticals, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

X4 Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 20 March 2026

Ownership

X4 Pharmaceuticals, Inc. (XFOR) Latest News

4 Nov

29 Oct

9 Oct

8 Oct

24 Sep

8 Sep

6 Aug

21 May

18 May

6 May

29 Apr

17 Mar

27 Feb

16 Feb

3 Feb

12 Jan

24 Dec

8 Dec

24 Nov

18 Nov

5 Nov

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

X4 Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 20 March 2026

Ownership

X4 Pharmaceuticals, Inc. (XFOR) Latest News

4 Nov

29 Oct

9 Oct

8 Oct

24 Sep

8 Sep

6 Aug

21 May

18 May

6 May

29 Apr

17 Mar

27 Feb

16 Feb

3 Feb

12 Jan

24 Dec

8 Dec

24 Nov

18 Nov

5 Nov

Stockrow Weekly